Epigenetic therapy with hydralazine and valproate associated to cisplatin chemoradiation in FIGO stage IIIB. A phase II study
Pérez-Cárdenas Enrique, Trejo-Becerril Catalina, Taja-Chayeb Lucia and 13 more
BMC Cancer · 2007
doi:10.1186/1471-2407-7-s1-a28 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
ss Open Acce Meeting abstract Epigenetic therapy with hydralazine and valproate associated to cisplatin chemoradiation in FIGO stage IIIB. A phase II study Myrna Candelaria1, Lucely Cetina1, Alicia Garcia1, Talia Wegman-Ostrosky1, Elizabeth Robles1, Aurora Gonzalez-Fierro1, Carlos Lopez-Graniel2, Aaron Gonzalez2, David Cantu2, Lesbia Ribera3, Lucia Taja-Chayeb1, Catalina Trejo-Becerril1, Enrique Perez-Cardenas1, Carlos Perez-Plasencia1, Alma Chavez-Blanco1 and Alfonso Duenas-Gonzalez*1,4
Abstract licence: CC BY-NC-ND
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.